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A new series of N’-substituted benzylidene-2-(4-oxo-2-
phenyl-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide (5a–
5h) has been synthesized, characterized by FT-IR, NMR
spectroscopy and mass spectrometry and tested against
human monoamine oxidase (MAO) A and B. Only
(4-hydroxy-3-methoxybenzylidene) substituted compounds
gave submicromolar inhibition of MAO-A and MAO-B.
Changing the phenyl substituent to methyl on the unsaturated
quinazoline ring (12a–12d) decreased inhibition, but a less
flexible linker (14a–14d) resulted in selective micromolar
inhibition of hMAO-B providing insight for ongoing design.
quinazoline
scaffold head
hydrazido linker
substituted aromatic
tail
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21. Introduction
Depression has been reported to be the fourth global burden of disease, with nearly 12% of the global
disability-adjusted life years [1]. In the Kingdom of Saudi Arabia, improvements in socioeconomic
status have been shown to be associated with increased chronic diseases including chronic mental
diseases like depression [2–7]. Monoamine oxidases (MAO), enzymes containing covalently bound
flavin adenine dinucleotide (FAD) as the cofactor, are located on the mitochondrial outer membrane
where they oxidize various physiologically and pathologically important monoamines. These
neurotransmitters and hormones include serotonin, noradrenaline and dopamine that function to
regulate movement, emotion, reward, cognition, memory and learning [8–10].
The two isoforms of MAO (MAO-A and MAO-B) are characterized by different affinities for inhibitors
and different specificities for substrates [11,12]. MAO-A preferentially metabolizes serotonin, adrenaline,
and noradrenaline [13], whereas 2-phenylethylamine and benzylamine are predominantly metabolized
by MAO-B [14]. Tyramine and dopamine are common substrates for both isoenzymes [15]. The
therapeutic interest in monoamine inhibitors (MAOIs) covers two major categories: MAO-A inhibitors
are used mostly in the treatment of mental disorders, in particular depression and anxiety [16–18],
whereas MAO-B inhibitors are used in the treatment of Parkinson’s disease and are of interest against
Alzheimer’s disease [19,20].
A major goal of our group is to develop compounds capable of inhibiting monoamine oxidase A as a
target for the treatment of depression and psychological disorders. We have designed and synthesized
several series of compounds carrying 3-benzylquinoxaline and quinazoline scaffolds with selective
activity towards MAO-A [21–25]. Based on the results, we decided to change the scaffold from benzyl
quinoxaline to methyl and phenyl quinazolines as the prominent motif for discovery of variety of
biologically active compounds. To further explore the structure–activity relationships of the new
quinazoline class of MAO-A inhibitors, we have now synthesized and evaluated a series of
N’-substituted benzylidene-2-(6-chloro-4-oxo-2-aryl-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazides and
N’-substituted benzylidene-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazides for their ability to
inhibit the enzymatic activity of both MAO isoforms. The rationale of work design was built upon
different factors that include: (i) the presence of a hydrophobic nitrogen heterocyclic head (Quinazolyl
moiety), (ii) the presence of the hydrazido functionality (–CO–NH–N=) connected to the N atom via a
saturated carbon linker, and (iii) the presence of an electron-rich aromatic tail (Y =OH, OMe in type 5
compounds) (chart 1). We also prepared and examined a series of (E)-3-(substituted benzylideneamino)-
2-methylquinazolin-4(3H)-ones which contain imino functionality (–HC=N–) linker (compounds 14).2. Results and discussion
2.1. Organic synthesis
The synthetic route for the target compounds 5a–5h is depicted in scheme 1. Allowing isatoic anhydride
1a–1b to react with methyl glycine hydrochloride and triethylamine afforded the intermediate methyl (2-
aminobenzoyl)glycinate 2a–2b. The cyclocondensation of compound 2a–2b and aromatic aldehyde in
ethanol under reflux processed to furnish 3a–3d. One-pot three components synthetic route to type 3
was achieved using metal oxides nanoparticles [26]. Allowing isatoic anhydride to react with methyl
glycine hydrochloride, triethylamine and aromatic aldehyde in ethanol–water mixture in the presence
of catalytic amount of copper oxide nanoparticles led to the formation of 3a–3d in good yields. The
treatment of the ester 3a–3d with hydrazine hydrate afforded the corresponding hydrazides 4a–4d.
Their structures were confirmed by spectroscopic tools and secured by X-ray single crystal analysis of
compound 4c as a prototype (figure 1; electronic supplementary material, table S1).
Reaction of compounds 4a–4d with different aromatic aldehydes in ethanolic solution and keeping the
reaction mixture warm and stirring overnight furnished the desired products N’-benzylidene-2-(4-oxo-2-
phenyl-1,4-dihydroquinazolin-3(2H)yl)acetohydrazide derivatives 5a–5h. The NMR spectra of type 5
compounds reveal that they exist in two isomeric forms E and Z in dimethyl sulfoxide solution [27,28].
As a prototype, 1H NMR spectrum of 5d (figure 2) showed two sets of two doublets in 64 : 36 ratio for
the α-CH2 with coupling constant of 17.6 and 16.4 Hz at δ 3.64, 4.03 and 3.34, 4.53, respectively. The
hydrazono N=CH appeared as singlets at δ 7.82 and 8.03. In 13C NMR, the α-C resonated at δ 45.42
and 46.32. These assignments were supported by the 1H–1H COSY NMR spectrum which confirmed
head linker tail
lead structure
MAO-A activity PIC50 = 7.8
benzylquinoxaline scaffold
hydrazido linker
substitiuted aromatic ring
12a–d
5a–h
14a–d
Y = H, OH, OMe
Chart 1. Planned modification and newly designed quinazolyl hydrazine derivative monoamine inhibitors.
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3the correlation assignments of α-CH2 and provided support to full peak assignments. The sp
3CH resonated
at δ 6.00 and correlated to two signals at δ 7.25 and 7.33 ppm of the NHs.
On the other hand, an attempt to accelerate the reaction 4b and vanillin using few drops of acetic acid
and heating the reactionmixture to reflux led to ring opening and the precipitation of 6, as evident byNMR.
Themethylene protons showed one signal at δ 3.64 that correlates to carbon at δ 44.75 in heteronuclear single
quantum coherence spectroscopy (HSQC) spectrum indicating the loss of the sp3CH chiral centre.
To synthesize the quinazolin-3(4H)-yl)acetohydrazide analogue 7 (scheme 2), the methyl 2-(4-oxo-2-
phenyl-1,4-dihydroquinazolin-3(2H)-yl)acetate 3a was oxidized with 2,3-dichloro-5,6-dicyano-1,4-
benzoquinone (DDQ) to afford methyl 2-(4-oxo-2-phenylquinazolin-3(4H)-yl)acetate 8 [29].
Hydrazinolysis of 8 with hydrazine hydrate furnished 7 which was confirmed by spectral data and its
melting point matches the literature [30].
For the comparative study, compounds 12a–12d were prepared using a method modified from the
one reported earlier [31,32] (scheme 3) starting from 2-methyl-4H-benzo[d][1,3]oxazin-4-one 9 to 10
which upon hydrazinolysis furnished 11. The reaction of compound 11 with aromatic aldehydes in
dimethylformamide and few drops of acetic acid furnished N’-substituted benzylidene-2-(2-methyl-4-
oxoquinazolin-3(4H)-yl)acetohydrazide 12a–12d in good yield. According to the obtained NMR
spectra, these compounds exist as a mixture of E and Z (see Experimental section) and not as
reported earlier as a single isomers [31,32].
The reaction sequence that led to the synthesis of (E)-3-(substituted benzylideneamino)-2-
methylquinazolin-4(3H)-one 14a–14d is shown in scheme 4. Thus, compound 9 was converted to 13
by reacting with hydrazine hydrate [33], which upon condensation with various aromatic aldehydes
MeO2CCH2NH2.HCl/Et3N
ArCHO/CuONP
EtOH:H2O
MeO2CCH2NH2 · HCl/
Et3N
ArCHO/
EtOH
1 3
2
a X = H Ar = C6H5
b X = Cl Ar = C6H5
c X = Cl Ar = 4-OMeC6H4
d X = Cl Ar = 2-OMeC6H4
N2H4
4
ArCHO/EtOH
5 E
a X = H
b X = Cl
a X = H Ar = C6H5
b X = Cl Ar = C6H5
c X = Cl Ar = 4-OMeC6H4
d X = Cl Ar = 2-OMeC6H4
a X = H Ar = C6H5 E/Z 70 : 30
b X = H Ar = 4-OHC6H4 E/Z 70 : 30
c X = H Ar = 4-OMeC6H4 E/Z 70 : 30
d X = H Ar = 3-OMe, 4OHC6H3 E/Z 64 : 36
e X = Cl Ar = C6H5 E/Z 73 : 27
f X = Cl Ar = 4-OMeC6H4 E/Z 67 : 33
g X = Cl Ar = 4-OHC6H4 E/Z 71 : 29
h X = Cl Ar = 3-OMe, 4OHC6H3 E/Z 67 : 33
a X = H
b X = Cl
+ Z isomer
ArCHO/
MeOH, AcOH-heat
X = Cl Ar = 3-OMe, 4OHC6H3
6
Scheme 1. Synthesis of compounds 3, 4, 5 and 6.
Figure 1. Perspective drawing of compound 4c.
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5d (E) 5d (Z)
Figure 2. Structures of the E/Z isomers of 5d.
3a
DDQ N2H4
EtOAc, rt MeOH, heat
8 7
Scheme 2. Synthetic route to compound 7.
MeO2CCH2NH2.HCl
Ac2O,
Et3N,120°C 1 h
N2H4, EtOH
reflux 5 h
12
a Ar=C6H5 E/Z 80 : 20
b Ar=4-OHC6H4 E/Z 77 : 23
c Ar=4-OMeC6H4 E/Z 78 : 22
d Ar=3-OMe, 4OHC6H3 E/Z 81 : 19
9 10
11E
+ Z isomer
reflux 3 h
ArCHO
DMF, AcOH
reflux 5 h
Scheme 3. Synthesis of compounds 12.
a Ar = C6H5
b Ar = 4-OHC6H4
c Ar = 4-OMeC6H4
d Ar = 3-OMe, 4OHC6H3
9 13 14
N2H4
MeOH, heat
ArCHO
MeOH, AcOH,
heat
Scheme 4. Synthetic route to compounds 14.
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Table 1. Inhibition of MAO activity.
compound
% inhibition at 10 μMa IC50 (μM)
b
hMAO-A hMAO-B hMAO-A hMAO-B
3a −6 38 none 5.28 ± 1.44 (40%)
3b 10 34
3c −3 10
3d 0 27
4b 6 31
4c 0 27
4d 0 28
5a 19 55 6.2 ± 0.95 10.0 ± 1.1
5b 6 36 none 83
5d 71 70 0.27 ± 0.06 0.75 ± 0.18
5e 10 19
5g 22 36 4.34 ± 1.31 11.0 ± 4.0
5h 70 72 0.31 ± 0.11 0.44 ± 0.1
6 none 12 (rate increases)c 9.0 ± 2.3
11 15 19 >100
13 −8 23
12a 6 26
12b 16 16 >100
12c 5 21
12d 27 52 1.41 ± 0.47 (32%) 3.62 ± 0.69
14a 5 40 6.84 ± 0.76 (77%)
14b 14 52 4.64 ± 0.41 (77%)
14c 8 44 6.75 ± 1.06 (73%)
14d 11 44 5.93 ± 1.02 (77%)
safinamide 11 90 0.08 [39]
harmine 100 17 0.009 ± 0.001 (100%) 11.6 ± 3.1
aObserved inhibition (% = 100 × rate with inhibitor/rate without inhibitor). Values are average of two independent experiments
with less than 15% difference.
bIC50 values ± s.d. for two independent experiments with 22 points each. The maximum inhibition (%) is given in parentheses if
less than 95%.
cThis compound (6) is oxidized by MAO-A so is a substrate (KM= 35.5 µM) inducing H2O2 production in the absence of tyramine.
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6furnished 14a–14d [34–38]. Their structures were found in agreement with the assigned molecular
structure and confirmed by IR, NMR spectroscopy and mass spectrometry.
2.2. MAO inhibition
All compounds were screened for inhibition of the activity of membrane-bound human MAO-A and
MAO-B at 10 µM in the presence of tyramine at 2 ×KM (0.8 mM for MAO-A and 0.32 mM for MAO-B)
(table 1). Apart from 5d, 5h, 11 and 12b, which gave equal inhibition of MAO-A and MAO-B in this
screen, the compounds were slightly selective for MAO-B (see electronic supplementary material,
figure S1). For the compounds that gave more than 30% inhibition, the IC50 was determined using
seven concentrations of each compound (0.01–300 µM) with tyramine substrate at 2 × KM. The MAO-A
and MAO-B IC50 values for these selected compounds are given in table 1 accompanied by the
maximum extent of the inhibition observed. Incomplete inhibition of activity could arise either from
0.7
0.6
0.5
0.4
0.3
0.2
0.1
0 1008060
[compound] (mM)
ra
te
 (r
fu 
s–1
)
4020
Figure 3. Oxidation of 6 (squares) but not 12d (triangles) by MAO-A. The concentration of compound was varied in the standard
assay coupled to the production of H2O2 but in the absence of the substrate tyramine.
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7indirect effects on these enzymes or from the compounds acting as substrates at the highest
concentrations. Only compounds 5a–5h, 12d and 14a–14d can be said to be classical inhibitors with
5a, 5h and 12d inhibiting both MAO-A and MAO-B. By contrast, 14a–14d were highly MAO-B
selective. The best inhibitors of MAO-A were 5d and 5h with submicromolar IC50 values (0.27 ± 0.06
and 0.31 ± 0.06 µM, respectively). These compounds were slightly less effective against MAO-B activity
(IC50 values 0.75 and 0.44 µM, respectively). Having both 3-OCH3 and 4-OH substituents on the tail
aryl group was important for high affinity, as seen also in 5h and 12d.
There was no difference in the inhibition without or with 30 min preincubation of MAO with the
compounds. This and the restoration of full activity upon dilution (×100) indicated that the inhibition
was reversible. For both MAO-A (with 5h or 12d) and MAO-B (with 12d or 14b), increasing the
substrate concentration in the assay increased the rate of reaction, suggesting competitive inhibition.
Compound 6 in the screening assay with 10 µM inhibitor gave an increased rate of appearance of
fluorescence indicating faster production of the product H2O2 (not the slower rate observed with other
compounds that inhibit MAO activity). When incubated with MAO-A in the absence of the normal
substrate, 6 (but not 12d) gave a measurable rate of H2O2 production, as shown in figure 3. Thus, 6
binds to and is oxidized by MAO-A. The Vmax for oxidation of 6 by MAO-A was 77% of the Vmax for
tyramine under the same conditions and the KM was 35.5 ± 7.8 µM.
2.3. Molecular docking simulation
The energy minimum structures of human MAO-A and MAO-B after removing covalent ligands
(clorgyline for 2BXR and deprenyl for 2BYB) were used as the models (electronic supplementary
material, figure S2).
The MAO-A binding site formed of a single cavity extends from the flavin ring to the cavity-shaping
loop consisting of residues 210–216. The volume of this cavity is estimated to be approximately 550 Å3
and is lined by aliphatic and aromatic residues, which are quite hydrophobic. In addition, two
cysteine residues are located near the entry of the catalytic site that share in the interaction. The MAO-
A active site lacks the MAO-B constriction allowing bulkier molecules to approach the aromatic cage
of FAD, Tyr407 and Tyr444 [40].
The active site of hMAO-B is small in volume compared to MAO-A but shows the same hydrophobic
nature. The MAO-B active site entrance is surrounded by hydrophobic amino acid residues (Leu171,
Tyr326, Phe168, Ile198 and Ile199), followed by a narrow hydrophobic tunnel leading to the aromatic
cage lined by the isoalloxazine of FAD, Tyr398 and Tyr435 [40].
The interactions of the phenylquinazoline head, acetohydrazide linker and aromatic tail with amino
acid residues in the active sites of MAO-A and MAO-B are shown in figure 4 and listed in electronic
supplementary material, table S1. The selective 14b (E-form) derivative is well tolerated in the MAO-B
pocket, binds close to the FAD and forms stable direct hydrogen bonds via the OH and indirectly to
two residues Gln57 (2.3 Å) and Lys296 (2.5 Å) (figure 4, top). The scaffold binds to the residues
Gln206, Tyr326, Thr201 and Ile199. The methyl group is well tolerated through hydrophobic
N N
N
O
O
H
Val
A93
Leu
A97
Ile
A180
Asn
A181
Ile
A207
Phe
A208
Ser
A209
Val
A210
Gly
A214
Cys
A323
Thr
A336
Leu
A337
Tyr
A407
Tyr
A444
FAD
B600
N
N N
O
O
H
Gly
A57
Tyr
A60
Phe
A168
Leu
A171
Cys
A172
Ile
A199
Thr
A201
Gln
A206
Lys
A296
Ile
A316
Tyr
A326 PheA343
FAD
B600
H2O
H2O
Cl
N
N
O
N
NO
O
HH
H Tyr
A69
Val
A70
Gly
A71
Gln
A74
Leu
A97
Ile
A180
Arg
A206
Ile
A207
Phe
A208
Ser
A209
Glu
A216
Cys
A323
Met
A324
Ile
A325
Ile
A335
Thr
A336
Leu
A337
Phe
A352
Trp
A441
Tyr
A444 FAD
B600
Cl
N
N
H
O
N
N O
O
H
H
Pro
A102
Phe
A168
Leu
A171
Cys
A172
Ile
A198
Ile
A199
Ser
A200
Gln
A206
Ile
A316
Tyr
A326
Phe
A343
Tyr
A398
Tyr
A435
FAD
B600
H2O
Cl
N
N
O
N
N O
O
H
O
H
H
Tyr
A69
Val
A70
Gly
A71
Pro
A72
Leu
A97
Arg
A109
Gly
A110
Ile
A180
Asn
A181
Ile
A207
Phe
A208 Ser
A209
Val
A210
Gln
A215
Glu
A216
Ile
A325
Ile
A335
Leu
A337
Phe
A352
Tyr
A407
Tyr
A444
FAD
B600
Cl
N
N
O
N
N O
O OH
H
H
Leu
A167
Phe
A168
Leu
A171
Ile
A198
Ile
A199
Thr
A201
Gln
A206
Tyr
A326
Leu
A328
Met
A341
Phe
A343
Tyr
A398
Gly
A434
Tyr
A435
FAD
B600
H2O
H2O
MAO-A analysis MAO-B analysis
14b 14b (B-selective)
no inhibition
affinity DG = –18 kcal mol–1
IC50 = 4.64 ± 0.41 mM (77%)
affinity DG = –22 kcal mol–1
5g (A-selective) 5g  
IC50 = 4.43 ± 1.31 mM
affinity DG = –21 kcal mol–1
IC50 = 11 ± 4.0 mM
affinity DG = –17 kcal mol–1
5h (non-selective)
polar
acidic
basic
greasy backbone donor
backbone acceptor
sidechain donor
sidechain acceptor
metal contact
solvent contact
solvent residue
metal complex
arene-arene
arene-cation
proximity
contour
ligand
exposure
receptor
exposure
5h (non-selective)
IC50 = 0.31 ± 0.11 mM
affinity DG = –22 kcal mol–1
IC50 = 0.44 ± 0.1 mM
affinity DG = –21 kcal mol–1
Figure 4. Interactions of selective and non-selective inhibitors with MAO-A and MAO-B.
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Table 2. Detailed docking data of representative compounds with MAO-A and MAO-B.
ID fragment MAO-A MAO-B interaction type
14b methyl quinazoline
head
hydrophobic interaction with
terminal pocket formed of
Gly214, Phe208, Val93, Leu97,
Lys323 and Thr336
hydrophobic interaction with
terminal pocket formed of
Tyr80, Ile316, Cys172 and
Ile199
hydrophobic and
hydrogen
bonding
hydrogen bonding through the
(C=O) to Ser209 with 2.2 Å
Bidirectional hydrogen bonding
through the (C=O) to Tyr325
with 2.4 Å and H2O-Thr201,
with 4.6 Å
Imino linker Vdw interaction with terminal
pocket formed of Ser209
Vdw interaction with terminal
pocket formed of Leu171
Vdw interaction
aromatic ring tail aromatic stacking tolerated in cage
formed of Phe208 and FAD
hydrophobic interaction with
terminal pocket formed of
Gly206 and Phe343
hydrophobic and
hydrogen
bonding
hydrogen bonding through the
( p-OH) to Ile180 with 2.7 Å
bidirectional hydrogen bonding
through the ( p-OH) to FAD
with 2.6 Å and H2O-Gly57,
with 4.5 Å
5g Phenyl
dihydroquinazoline
head
hydrophobic interaction with
terminal pocket formed of
Leu337, Ile207, Ile325 and
Phe208
aromatic stacking tolerated in cage
formed of Tyr398
hydrophobic and
hydrogen
bondinghydrogen bonding through (NH)
fragment to Tyr435 with
distance 2.3 Å
acetohydrazide linker bidirectional hydrogen bonding
through the (C=O) and (=N) to
Ser209 with 1.95 and 2.20 Å
hydrophobic interaction with
terminal pocket formed of
Tyr326 and Cys172
hydrophobic and
hydrogen
bonding
aromatic ring tail bidirectional hydrogen bonding
through the ( p-OH) to Gly74
and Tyr69 with 1.85, 2.9 Å
hydrogen bonding through the
( p-OH) to Pro102 with 2.51 Å
hydrophobic and
hydrogen
bonding
hydrophobic interaction with
terminal pocket formed of
Gly71, Tyr69, Tyr444 and FAD
hydrophobic interaction with
terminal residue Ile199, Leu171
and Ile316
5h Phenyl
dihydroquinazoline
head
hydrophobic interaction with
terminal pocket formed of Tyr69,
Ile207, Ile335, Tyr407 and Val70
hydrophobic interaction with
terminal pocket formed of
Phe343, Tyr435 and FAD
hydrophobic
interaction
hydrogen bonding through the (C=
O) to Ser209 with 2.7 Å
hydrogen bonding through the
(C=O) to Tyr435 with 2.3 Å
and H2O-Ile198 with 4.9 Å
hydrophobic and
hydrogen
bonding
aromatic stacking tolerated in cage
formed of Tyr398
acetohydrazide linker aromatic stacking tolerated in cage
formed of Phe208
hydrogen bonding through the
(C=O) to Gln206 with 3.1 Å
hydrophobic and
hydrogen
bonding
aromatic ring tail hydrogen bonding through the ( p-
OH) to Val210 with 2.4 Å
hydrophobic interaction with
terminal pocket formed of
Phe168, Leu328 and Tyr326
hydrophobic and
hydrogen
bondingVdw interaction with terminal
pocket formed of Leu97
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R.Soc.Open
Sci.7:200050
9
royalsocietypublishing.org/journal/rsos
R.Soc.Open
Sci.7:200050
10interaction with Phe168 and Leu171. By contrast, the docking of 14b (E-form) in the MAO-A formed
unfavourable interactions in the pocket. The binding analysis of the MAO-A selective 5g (Z-form)
showed favourable interaction in the pocket with stable hydrogen bonding interactions through the
terminal tail OH with Tyr69, FAD and Gln74 (figure 4, middle). It also binds through the
acetohydrazide linker to the Ser209 by dual hydrogen bonds (2.72 and 2.48 Å). The phenylquinazoline
head had hydrophobic interaction with the pocket formed of Phe352, Ile180, Leu337 and Phe208
residues. By contrast, MAO-B with 5g (Z-form) showed serious clashes with both head and tail parts,
and reversed placement compared to 14b. The non-selective compound 5h revealed the head
phenylquinoxaline close to the FAD and good interaction behaviour towards the both targets
(figure 4, bottom). All molecular placement data of active compounds within the binding pockets of
MAO-A compared to MAO-B are summarized in table 2.
2.4. SAR analysis
MAO-A is inhibited only by the quinazoline compounds of type 5 (5a, 5d, 5g, 5h) and with only
micromolar potency, in contrast with our earlier 3-benzylquinoxaline-based compounds found to have
nM potency [24]. For MAO-B, compounds 5a, 5d, 5g, 5h and 12d gave full inhibition with micromolar
affinity. The 14 series all gave 75% inhibition in the dose–response curves and IC50 values about 6
μM. None of the series 14 compounds inhibited MAO-A, so these are selective MAO-B inhibitors.
Interestingly, MAO-A and MAO-B were equally inhibited by the precursor 11, and by 12b, 5d and 5h,
all with substituted aryl groups as the aromatic tail.
Considering first the phenylquinazoline head shown in the design strategy in chart 1 (type 5
compounds), the addition of Cl to the head group had no effect. However, switching the 2-methyl in
12 to the 2-phenyl in 5 improved inhibition of both MAO-A and MAO-B activity, from no inhibition
to IC50 values below 10 μM (table 1). Changing the linker from the acetylhydrazide found in 5 and 12
to the imine found in 14 introduced selectivity for MAO-B. Both 5a and 14a have IC50 values below
10 µM for MAO-B but 5a inhibits MAO-A with an IC50 of 4.4 µM, whereas 14a does not inhibit MAO-
A. In the third region, the addition of 4-OH and 3-OCH3 to the aromatic tail improves the IC50 by
more than 10-fold (5a with MAO-B is 10 µM, but 5d is 0.75 µM; 6.2 and 0.27 µM for MAO-A). By
contrast, with only the 4-OH, compounds 5b and 5g are poor inhibitors. This difference might be due
to the changed interactions in the active site (figure 4 and table 2).3. Conclusion
Prior work showed that the 3-benzylquinoxaline and quinazoline scaffolds gave a good basis for selective
inhibition of MAO-A. Here, compounds were prepared to explore different synthetic methodologies and
study the influence of the heterocyclic head group, the hydrazido linker and the aromatic tail in the
inhibition. The N’-substituted benzylidene-2-(6-chloro-4-oxo-2-aryl-1,4-dihydroquinazolin-3(2H)-
yl)aceto-hydrazide series provided the most potent inhibitors, namely 5d (IC50 = 0.25 µM, threefold
selective for MAO-A) and 5h (0.31 µM on MAO-A and 0.44 µM on MAO-B). Removing the aryl
tail substituents resulted in decreased inhibition (5a IC50 = 6 µM). The shorter less flexible linker in
(E)-3-(substituted benzylideneamino)-2-methylquinazolin-4(3H)-one compounds 14a–14d resulted
in inhibition selective for MAO-B with IC50 values in the micromolar range. Molecular docking
revealed the importance of interactions near the FAD for good affinity.4. Experimental section
4.1. General chemistry
Melting points were determined with a Mel-Temp apparatus and are uncorrected. Nuclear magnetic
resonance spectra (1H NMR and 13C NMR spectra) were recorded using a Bruker 400 MHz
spectrometer with the chemical shift values reported in δ units (part per million) and the coupling
constant (J ) in hertz. Infrared data were obtained using a Perkin–Elmer 1600 series Fourier transform
instrument as KBr pellets. Mass spectra were recorded on Brucker MALDI microflex and Agilent 6320
Ion Trap equipped with an electrospray ionization interface mass spectrometer. Elemental analyses
were performed on Perkin–Elmer 2400 elemental analyser, and the values found were within ±0.3% of
the theoretical values. The follow-up of the reactions and checking the purity of the compounds were
roya
11made by TLC on silica gel-protected aluminium sheets (Type 60 GF254, Merck) and the spots were
detected by exposure to UV-lamp at λ 254 nm for few seconds. Compounds of type 12 [31,32] and 14
were prepared according to the reported procedure [34–38] (electronic supplementary material). lsocietypublishing.org/journa4.1.1. General procedure for the preparation of methyl (2-aminobenzoyl)-glycinate (2a–2b)
In round bottom flask (500 ml), a mixture of glycine methyl ester hydrochloride (1.26 g, 10 mmol),
triethylamine (1 ml) was dissolved in ethanol (300 ml) and heated in water both at 60–70°C for 7 min,
isatoic anhydride (10 mmol) was added to the mixture (portion wise) over a period of 30 min with
stirring at 80°C. The mixture was allowed to heat under reflux for extra 30 min. The solvent was
evaporated and the residue was used in the next step without further purification. l/rsos
R.So4.1.1.1. Methyl (2-aminobenzoyl)glycinate (2a) [25]
Yield: 69%; mp 75–77°C. c.Open
Sci.7:24.1.1.2. Methyl (2-amino-5-chlorobenzoyl)glycinate (2b)
Yield: 71%; mp 155–157°C. IR (KBr): 3240, 3182 (NH2 and NH), 1718 (C=O, ester), 1670 (C=O, amide)
cm−1. 000504.1.2. General procedure for the preparation of methyl 2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-
3(4H)-yl)acetate (3a–3d)
Method A: To the solution of methyl (2-amino-5-substituted benzoyl)glycinate 2 (10 mmol) in ethanol
(50 ml) was added the appropriate aldehydes and four drops of acetic acid at room temperature. The
reaction mixture was heated under reflux for about 8 h and followed by TLC (EtOAc :MeOH 7 : 3).
The solvent was removed under vacuum and the crude product was recrystallized from ethanol,
filtered and washed with ethanol to afford the pure product.
Method B: Isatoic anhydride (6.13 mmol), triethylamine (0.619 g, 6.13 mmol), glycine methyl ester
hydrochloride (0.769 g, 6.13 mmol), the appropriate aldehyde (6.13 mmol) and CuO nanoparticles
(0.042 g, 0.613 mmol) were mixed in aqueous ethanol (EtOH : H2O 15 : 5) (20 ml). The reaction mixture
was heated under reflux for 8 h and followed by TLC (EtOAc :MeOH 7 : 3). The CuO nanoparticle
catalyst was separated by filtration and the filtrate was concentrated and left to cool to room
temperature. The product that precipitated out was filtered off and recrystallized from ethanol.4.1.2.1. Methyl-2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetate (3a)
Method A: yield: 79%; Method B: yield: 83%; mp 198–200°C [25]4.1.2.2. Methyl-2-(6-chloro-4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetate (3b)
Method A: yield: 77%; Method B: yield: 91%: mp 162–163°C; IR (KBr): 3375 (NH), 1750 (C=O, ester), 1630
(C=O, amide) cm−1; 1H NMR (400 MHz: DMSO-d6): δ 3.60 (s, 3H, OCH3), 3.63 (d, 1H, J 17.2 Hz, α-CH),
4.41 (d, 1H, J 17.2 Hz, α-CH), 5. 98 (s, 1H, sp3 C-H), 6.74 (d, 1H, J 8 Hz, Ar-H), 7.31 (d, 1H, J 8 Hz, Ar-H),
7.40 (bs, 5H, Ar-H), 7.59 (bs, 1H, NH), 7.63 (s, 1H, Ar-H). 13C NMR (100 MHz: DMSO- d6): δ 46.32, 52.36,
71.95, 115.43, 116.89, 121.37, 127.07, 127.32, 129.23, 129.59, 133.99, 139.81, 146.39, 162.23, 169.46. Anal.
Calcd for C17H15ClN2O3: C, 61.73; H, 4.57; N, 8.47. Found: C, 62.46; H, 4.61; N, 8.45.4.1.2.3. Methyl 2-(6-chloro-2-(4-methoxyphenyl)-4-oxo–1,2-dihydroquinazolin-3(4H)-yl)acetate (3c)
Method B: yield: 55%: mp 148–150°C. IR (KBr): 3300 (NH), 1710 (C=O, ester), 1630 (C=O, amide) cm−1.
1H NMR (400 MHz: DMSO-d6): δ 3.58 (d, 1H, J 17.2 Hz, α-CH), 3.60 (s, 3H, OCH3), 3.75 (s, 3H, OCH3),
4.34 (d, 1H, J 17.2 Hz, α-CH), 5.92 (s, 1H, sp3 C-H), 6.75 (d, 1H, J 8.4 Hz, Ar-H), 6.96 (d, 2H, J 8.2 Hz, Ar-
H), 7.32 (d, 1H, J 8.4 Hz, Ar-H), 7.34 (d, 2H, J 8.2 Hz, Ar-H), 7.53 (bs, 1H, NH), 7.58 (s, 1H, Ar-H). 13C
NMR (100 MHz: DMSOd6): δ 46.00, 52.35, 55.66, 71.72, 114.53, 115.37, 116.90, 121.54, 127.04, 129.08,
131.41, 134.06, 146.75, 160.29, 162.45, 169.47. Anal. Calcd for C18H17ClN2O4: C, 59.92; H, 4.75; N, 7.76.
Found: C, 60.01; H, 4.61; N, 7.55.
royalsocietypublishing.
124.1.2.4. Methyl 2-(6-chloro-2-(2-methoxyphenyl)-4-oxo–1,2-dihydroquinazolin-3(4H)-yl)acetate (3d)
Method B: yield: 55%: mp 152–154°C. IR (KBr): 3300 (NH), 1751 (C=O, ester), 1639 (C=O, amide) cm−1.
1H NMR (400 MHz: DMSO-d6): δ 3.60 (s, 3H, OCH3), 3.62 (d, 1H, J 17.2 Hz, α-CH), 3.79 (s, 3H, OCH3),
4.41 (d, 1H, J 17.2 Hz, α-CH), 6.22 (s, 1H, sp3 C-H), 6.76 (d, 1H, J 7.6 Hz, Ar-H), 6.93 (t, 1H, J 7.6 Hz, Ar-
H), 7.07 (d, 1H, J 7.6 Hz, Ar-H), 7.20 (d, 1H, J 7.6 Hz, Ar-H), 7.27 (d, 1H, J 7.6 Hz, Ar-H), 7.28 (bs, 1H,
NH), 7.34 (t, 1H, J 7.6 Hz, Ar-H), 7,58 (s, 1H, Ar-H). 13C NMR (100 MHz: DMSO-d6): δ 44.82, 51.04,
54.84, 65.44, 111.04, 114.05, 115.60, 119.79, 119.94, 125.85, 126.12, 126.24, 129.62, 132.60, 145.40, 156.09,
161.23, 168.43. Anal. Calcd for C18H17ClN2O4: C, 59.92; H, 4.75; N, 7.76. Found: C, 60.14; H, 4.73; N, 7.62. org/journal/rsos
R.Soc.Ope4.1.3. General procedures for the preparation of 2-(6-substituted-4-oxo-2-phenyl-1,2 dihydroquinazolin-
3(4H)-yl)acetohydrazide (4a–4d)
To a solution of compound 3 (3.1 mmol) in methanol (10 ml), hydrazine hydrate (80%) (0.4 ml) was
added. The reaction mixture was heated under reflux for 3 h and monitored by TLC (EtOAc :MeOH
7 : 3). The solution was concentrated under vacuum and the product that precipitated out was filtrated
off, recrystallized from ethanol and dried.n
Sci.7:2004.1.3.1. 2-(4-Oxo-2-phenyl-1,2-dihydroquinazolin-3(4H-yl)acetohydrazide (4a)
Yield 77%; mp 215–218°C [25]. 0504.1.3.2. 2-(6-Chloro-4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide (4b)
Yield 75%; mp 184–185°C; IR (KBr): 3320, 3300 (NH2 and NH), 1675 (C=O, amide) cm
−1. 1H NMR
(400 MHz: DMSO-d6): δ 3.18 (d, J 16 Hz, 1H, α-CH), 4.20 (s, 2H, NH2), 4.5 (d, J 16 Hz, 1H, α-CH),
5.96 (s, 1H, sp3 CH) 6.72 (d, J 8 Hz, 1H, Ar-H), 7.28 (d, J 8 Hz, 1H Ar-H), 7.39 (bs, 5H Ar-H), 7.52 (s,
1H, NH), 7.59 (s, 1H, Ar-H), 9.052 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6): 45.62, 71.98,
115.72, 116.75, 121.22, 127.08, 127.27, 129.2, 129.50, 133.73, 140.02, 146.16, 162.24, 167.45. Anal. Calcd
for C16H15ClN4O2: C, 58.10; H, 4.57; N, 16.94. Found: C, 57.95; H, 4.61; N, 16.81.4.1.3.3. 2-(6-Chloro-2-(4-methoxyphenyl)-4-oxo-1,2-dihydroquiazolin-3(4H)-yl)acetohydrazide (4c)
Yield 86%; mp 159–160°C; IR (KBr): 3310, 3230 (NH2 and NH), 1690 (C=O, amide) cm
−1. 1H NMR
(400 MHz: DMSO-d6): δ 3.56 (d, J 17.2, 1H, α-CH), 3.60 (s, 3H, NH2 and NH), 3.75 (s, 3H, OCH3), 4.34
(d, J 17.2 HZ, 1H, α-CH), 5.92 (s, 1H, sp3 CH), 6.72 (d, J 8.4 Hz, 1H, Ar-H), 6.96 (d, J 8 Hz, 2H, Ar-H),
7.31 (d, J 8.4 Hz, 1H Ar-H), 7.34 (d, J 8 Hz, 2H, Ar-H), 7.49 (bs, 1H, NHCO), 7.58 (s, 1H, Ar-H). 13C
NMR (DMSO-d6, 100 MHz): δ 51.26, 54.60, 70.72, 113.47, 114.39, 115.83, 120.31, 126.02, 127.84, 130.36,
132.85, 145.53, 159.29, 161.34, 168.44. Anal. Calcd for C17H17ClN4O3: C, 56.59; H, 4.75; N, 15.53.
Found: C, 56.35; H, 4.72; N, 15.65.4.1.3.4. 2-(6-Chloro-2-(2-methoxyphenyl)-4-oxo-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide (4d)
Yield 87%; mp 149–151°C. IR (KBr): 3310, 3200 (NH2 and NH), 1680 (C=O, amide) cm
−1. 1H NMR
(400 MHz: DMSO-d6): δ 3.60 (s, 3H, NH, NH2), 3.62 (d, J 17.2 Hz, 1H, α-CH), 3.79 (s, 3H, OCH3), 4.35
(d, J 17.2 Hz, 1H,α-CH), 6.22 (s, 1H, sp3 CH), 6.76 (d, J 8 Hz, 1H, Ar-H), 6.93 (t, 2H, J 7.2 Hz, Ar-H),
7.07 (d, J 8 Hz, 1H, Ar-H), 7.20 (d, J 7.2 Hz, 1H, Ar-H), 7.26–7.28 (m, 2H, Ar-H, NHCO), 7.34 (t, J
8 Hz, 1H, Ar-H), 7.57 (s, 1H, Ar-H). 13C NMR (DMSO-d6, 100 MHz): δ 52.30, 56.21, 66.75, 111.94,
115.13, 116.84, 120.86, 121.03, 126.91, 127.19, 127.31, 130.75, 133.80, 146.70, 157, 162.25, 169.41. Anal.
Calcd for C17H17ClN4O3: C, 56.59; H, 4.75; N, 15.53. Found: C, 56.43; H, 4.75; N, 15.57.4.1.4. General procedures for the preparation of N’-substituted benzylidene-2-(4-oxo-2-phenyl-1,4-
dihydroquinazolin-3(2H)-yl)acetohydrazide (5a–5h)
To a solution of compound 4 (0.25 g, 6.85 mmol) in ethanol (20 ml), the appropriate aldehyde
(6.85 mmol) was added and the mixture was stirred for 24 h at temperature between 25 and 60°C and
monitored by TLC. When the reaction is over, the mixture was concentrated and left to cool to room
temperature. The product that precipitated out was filtrated off, recrystallized from ethanol and dried.
royalsocietypublishing.org/journal/rsos
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134.1.4.1. N’-Benzylidene-2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide (5a)
Yield: 88%; mp 223–225°C. IR (KBr): 3304 (NH), 1689, 1640 (C=O, amide) cm−1. Isomer E (70%): 1H NMR
(400 MHz: DMSO-d6): δ 3.66 (d, 1H, J = 17.2 Hz, α-CH), 5.05 (d, 1H, J = 17.2 Hz, α-CH), 5.94 (s, 1H, sp
3 C-
H), 6.70–6.72 (m, 2H, Ar-H), 7.25–7.69 (m, 13H, Ar-H and NH), 7.93 (s, 1H, CH=N), 11.49 (s, 1H, NHCO).
13C NMR (100 MHz: DMSO-d6): δ 45.47, 72.22, 114.73, 114.79, 117.67, 127.19, 127.58, 128.11, 129.20, 129.29,
130.34, 133.94, 134.35, 140.29, 143.95, 147.04, 147.74, 163.56, 169.54. Isomer Z (30%): 1H NMR (400 MHz:
DMSO-d6): δ 3.12 (d, 1H, J = 16.8 Hz, α-CH), 4.37 (d, 1H, J = 16.8 Hz, α-CH), 5.92 (s, 1H, sp
3 C-H), 6.70–
6.72 (m, 2H, Ar-H), 7.25–7.69 (m, 13H, Ar-H and NH), 8.15 (s, 1H, CH=N), 11.44 (s, 1H, NHCO). 13C
NMR (100 MHz: DMSO-d6): δ 46.40, 72.33, 114.57, 114.68, 117.59, 127.40, 127.45, 127.50, 128.09, 129.17,
129.48, 130.50, 133.89, 134.06, 134.64, 147.53, 147,59, 163.59, 164.84. MS-MALDI: m/e 385.06 [M+1].
Anal. Calcd for C23H20N4O2: C, 71.86; H, 5.24; N, 14.57. Found: C, 71.02; H, 4.95; N, 14.41.
4.1.4.2. N’-(4-Hydroxybenzylidene)-2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide (5b)
Yield: 84%; mp 230–232°C. IR (KBr): 3275 (br) (OH and NH), 1685, 1650 (C=O, amide) cm−1. Isomer E
(70%): 1H NMR (400 MHz: DMSO-d6): δ 3.60 (d, 1H, J 17.2 Hz, α-CH), 5.03 (d, IH, J 17.2 Hz, α-CH)
5.99 (s, 1H, sp3 C-H), 6.71, 6.78, 7.27, 7.37, 7.67 (m, d, m, d, d, 14H, Ar-H and NH) 7.82 (s, 1H, CHN),
9.89 (s, 1H, OH), 11.28 (s, IH, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 45.43, 72.23, 114.71, 114.80,
116.14, 117.64, 125.38, 127.57, 128.10, 128.91, 129.20, 129.47, 133.92, 140.32, 144.24, 147.72, 159.65,
163.55, 169.18. Isomer Z (30%): 1H NMR (400 MHz: DMSO-d6): δ 3.33 (d, IH, J=16.4 Hz, α-CH), 4.52
(d, IH, J=17.2 Hz, α-CH), 5.99 (s, 1H, sp3 C-H), 6.71, 6.82, 7.27, 7.44, 7.51, (m, d, m, d, d, 14H, Ar-H
and NH), 8.03 (s, 1H, CHN), 9.93 (s, 1H, OH), 11.21 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6):
δ 46.30, 72.29, 114.60, 114.74, 117.64, 125.59, 127.43, 128.10, 129.20, 129.26, 129.45, 134.04, 140.32,
144.24, 147.35, 147.57, 159.83, 164.44, 169.18. MS-ESI: m/e 399.6 [M+1–2]. Anal. Calcd for
C23H20N4O3: C, 68.99; H, 5.03; N, 13.99. Found: C, 68.75; H, 4.79; N, 13.61.
4.1.4.3. N’-(4-Methoxybenzylidene)-2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide (5c)
Yield: 91%; mp 210–212°C. IR (KBr): 3300, 3290 (NH), 1690 (C=O, amide) cm−1. Isomer E (70%): 1H NMR
(400 MHz: DMSO-d6): δ 3.60 (d, 1H, J 17.2 Hz, α-CH), 5.03 (d, IH, J 17.2 Hz, α-CH) 5.99 (s, 1H, sp
3 C-H),
6.71, 6.78, 7.27, 7.37, 7.67, (m, d, m, d, d,14H, Ar-H and NH) 7.82 (s, 1H, CHN), 9.89 (s, 1H, OH), 11.28 (s,
IH, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 45.43, 72.23, 114.71, 114.80, 116.14, 117.64, 125.38, 127.57,
128.10, 128.91, 129.20, 129.47, 133.92, 140.32, 144.24, 147.72, 159.65, 163.55, 169.18. Isomer Z (30%): 1H
NMR (400 MHz: DMSO-d6): δ 3.33 (d, IH, J 16.4 Hz, α-CH), 4.52 (d, IH, J 16.4 Hz, α-CH), 5.99 (s, 1H,
sp3 C-H), 6.71, 6.82, 7.27, 7.44, 7.51, (m, d, m, d, d, 14H, Ar-H and NH), 8.03 (s, 1H, CHN), 9.93
(s, 1H, OH), 11.21 (s, IH, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 46.30, 72.29, 114.60, 114.74,
117.64, 125.59, 127.43, 128.10, 129.20, 129.26, 129.45, 134.04, 140.32, 144.24, 147.35, 147.57, 159.83,
164.44, 169.18. Anal. Calcd for C24H22N4O3: C, 69.55; H, 5.35; N, 13.52. Found: C, 70.05; H, 5.42; N, 13.65.
4.1.4.4. N’-(4-Hydroxy-3-methoxybenzylidene)-2-(4-oxo-2-phenyl-1,2-dihydroquinazolin-
3(4H)yl)acetohydrazide (5d)
Yield: 89%; mp 252–255°C. IR (KBr): 3300, 3295, 3200 (OH and NH), 1700 (C=O, amide) cm−1. Isomer E
(64%): 1H NMR (400 MHz: DMSO-d6): δ 3.64 (d,1H, J 17.6 Hz, α-CH), 3.76 (s, 3H, OCH3), 4.03 (d, 1H, J
17.6 Hz, α-CH), 6.00 (s, 1H, sp3 C-H), 6.70, 6.69, 7.00, 7.25–7.49, 7.68 (m, d, d, s, m, d, 13H, ArH and NH),
7.82 (s, 1H, CHN), 9.50 (s, 1H, OH), 11.32 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 45.42, 55.98,
72.25, 110.06, 114.73, 114.82, 116.03, 117.69, 121.40, 125.81, 127.62, 128.12, 129.17, 129.21, 129.48, 133.93,
140.25, 144.39, 147.77, 148.33, 149.14, 163.58, 169.25. Isomer Z (36%): 1H NMR (400 MHz: DMSO-d6): δ
3.34 (d, 1H, J 16.4 Hz, α-CH), 3.81 (s, 3H, OCH3), 4.53 (d, 1H, J 16.4 Hz, α-CH), 6.00 (s, 1H, sp
3 C-H),
6.70, 6.83, 7.06, 7.25–7.49, 7.68 (m, d, d, m, d, 13H, Ar-H +NH), 8.03 (s, 1H, CHN), 9.55 (s, 1H, OH),
11.25 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 46.32, 56.52, 72.35, 109.51, 114.62, 114.76,
115.88, 117.69, 122.41, 126.01, 127.62, 127.48, 128.12, 129.17, 129.21, 129.48, 134.06, 140.28, 147.60,
148.45, 149.38, 163.62, 164.49. MS-ESI: m/e 429.0 [M+1–2]. Anal. Calcd for C24H22N4O4: C, 66.97; H,
5.15; N, 13.02. Found: C, 67.05; H, 4.99; N, 13.14.
4.1.4.5. N’-Benzylidene-2-(6-chloro-4-oxo-2-phenyl-1,4-dihydroquinazolin-3(2H)-yl)acetohydrazide (5e)
Yield: 92%; mp 266–270°C. IR (KBr): 3390, 3224 (NH), 1699, 1637 (C=O, amide) cm−1. Isomer E (73%): 1H
NMR (400 MHz: DMSO-d6): δ 3.71 (d, 1H, J 17.2 Hz, α-CH), 5.04 (d, IH, J 17.2 Hz, α-CH), 6.02 (s, 1H, sp
3
royalsocietypublishing
14C-H), 6.75, 7.31, 7.27, 7.43, 7.57, 7,69 (d, d, m, m, d, 15H, Ar-H and NH), 7.99 (s, 1H, CHN), 11.51 (s, IH,
NHCO). 13C NMR (100 MHz: DMSO-d6): δ 45.63, 72.11, 115.82, 116.79, 121.28, 127.20, 127.51, 129.26,
130.34, 133.73, 134.33, 139.96, 144.07, 146.45, 162.41, 169.27. Isomer Z (27%): 1H NMR (400 MHz:
DMSO-d6): δ 3.63 (d, IH, I 16.4 Hz, α-CH), 4.52 (d, IH, J 16.42 Hz, α-CH), 6.02 (s, 1H, sp
3 C-H), 6.75,
7.31, 7.27, 7.43, 7.57, 7,69 (d, d, m, m, d, 15H, Ar-H and NH), 8.15 (s, 1H, CH =N), 11.44 (s, 1H,
NHCO). 13C NMR (100 MHz: DMSO-d6): δ 46.47, 72.23, 115.59, 116.79, 127.11, 127.40, 129.26, 129.59,
130.51, 133.85, 134.62, 146.32, 147.19, 162.44, 169.24. MS-ESI: m/e 417 [M+1–2]. Anal. Calcd for
C23H19ClN4O2: C, 65.95; H, 4.57; N, 13.38. Found: C, 66.02; H, 4.70; N, 13.52. .org/journal/rsos
R.Soc.Open
Sci.7:2000504.1.4.6. 2-(6-Chloro-4-oxo-2-phenyl-1,4-dihydroquinazolin-3(2H)-yl)-N’-(4-methoxybenzylidene)-
acetohydrazide (5f )
Yield: 90%; mp 138–140°C. IR (KBr): 3290, 3275 (NH), 1695, 1650 (C=O, amide) cm−1. Isomer E (67%): 1H
NMR (400 MHz: DMSO-d6): δ 3.68 (d, 1H, J 17.2 Hz, α-CH), 3.77 (s, 3H, CH3O), 5.03 (d, 1H, J 17.2 Hz, α-
CH), 6.03 (s, 1H, sp3 C-H), 6.76 (d, 1H, J 8.8 Hz, ArH), 6.95 (d, 2H, J 8.4 Hz, ArH), 7.31 (dd, 1H, J 8.4 Hz,
2.4 Hz, ArH), 7.38–7.64 (m, 9H, ArH and NH), 8.09 (s, 1H, CH =N), 11.32 (s, 1H, NHCO). 13C NMR
(100 MHz: DMSO-d6): δ 45.63, 55.10, 72.12, 114.74, 115.83, 116.78, 121.28, 126.94, 127.13, 127.52, 128.79,
129.26, 133.73, 139.96, 143.95, 146.45, 161.11, 162.42, 164.30, 169.02. Isomer Z (33%): 1H NMR
(400 MHz: DMSO-d6): δ 3.41 (d, 1H, J 16.4 Hz, α-CH), 3.80 (s, 3H, OCH3), 4.52 (d, 1H, J 16.4 Hz, α-
CH), 6.03 (s, 1H, sp3 C-H), 6.95 (d, 1H, J 8.4 Hz, ArH), 7.00 (d, 2H, J 8.4 Hz, ArH), 7.31 (dd, 1H, J
8.4 Hz, 2.4 Hz, ArH), 7.38–7.64 (m, 9H, ArH and NH), 7.88 (s, 1H, CH =N), 11.39 (s, 1H, NHCO). 13C
NMR (100 MHz: DMSO-d6): δ 46.41, 56.53, 72.22, 114.74, 115.61, 116.81, 121.28, 126.94, 127.10, 127.40,
129.12, 129.60, 133.84, 139.96, 146.32, 147.08, 161.28, 162.45, 164.33, 169.02. Anal. Calcd for
C24H21ClN4O3: C, 64.21; H, 4.72; N, 12.48. Found: C, 63.98; H, 4.84; N, 12.67.4.1.4.7. 2-(6-Chloro-4-oxo-2-phenyl-1,4-dihydroquinazolin-3(2H)-yl)-N’-(4-hydroxybenzylidene)acetohydrazide
(5g)
Yield: 84%; mp 236–240°C. Isomer E (71%): 1H NMR (400 MHz: DMSO-d6): δ 3.64 (d, 1H, J 17.2 Hz, α-
CH), 5.01 (d, 1H, J 17.2 Hz, α-CH), 6.01 (s, 1H, sp3 C-H), 6.74 (d, 1H, J 8.8 Hz, ArH), 6.78 (d, 2H, J 8.0 Hz,
ArH), 7.31 (dd, 1H, J 8.8 Hz, 2.4 Hz, ArH), 7.37–7.57 (m, 9H, ArH and NH), 7.60 (d, 1H, J 2.4 Hz, ArH),
9.90 (br s, 1H, OH), 11.31 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 45.61, 72.07, 115.81, 116.14,
116.77, 121.24, 125.35, 127.10, 127.49, 128.94, 129.27, 133.73, 140.00, 144.35, 146.43, 159.68, 162.37, 164.15,
168.89. Isomer Z (29%): 1H NMR (400 MHz: DMSO-d6): δ 3.35 (d, 1H, J = 16.0 Hz, α-CH), 4.50 (d, 1H, J
16.0 Hz, α-CH), 6.01 (s, 1H, sp3 C-H), 6.78 (d, 1H, J 8.0 Hz, ArH), 6.82 (d, 2H, J 8.4 Hz, ArH), 7.31 (dd, 1H,
J 8.8 Hz, 2.4 Hz, ArH), 7.37–7.57 (m, 9H, ArH and NH), 7.60 (d, 1H, J 2.4 Hz, ArH), 9.90 (br s, 1H, OH),
11.23 (s, 1H, NHCO). 13C NMR (100 MHz: DMSO-d6): δ 46.37, 72.15, 115.61, 116.14, 116.80, 121.24, 125.55,
127.25, 127.37, 129.27, 129.59, 133.84, 139.97, 146.29, 147.45, 159.85, 162.40, 164.15, 168.89. Anal. Calcd for
C23H19ClN4O3: C, 63.52; H, 4.40; N, 12.88. Found: C, 63.76; H, 4.33; N, 13.15.4.1.4.8. 2-(6-Chloro-4-oxo-2-phenyl-1,4-dihydroquinazolin-3(2H)-yl)-N’-(4-hydroxy-3-methoxybenzylidene)-
acetohydrazide (5h)
Yield: 93%; mp 240–242°C. Isomer E (67%): 1H NMR (400 MHz: DMSO-d6): δ 3.67 (d, 1H, J 17.6 Hz, α-
CH), 3.76 (s, 3H, CH3O), 5.01 (d, 1H, J 17.6 Hz, α-CH), 6.01 (s, 1H, sp
3 C-H), 6.74 (d, 1H, J 8.8 Hz, ArH),
6.78 (d, 1H, J 8.0 Hz, ArH), 6.99 (dd, 1H, J 8.4 Hz, 1.2 Hz, ArH), 7.11 (d, 1H, J 1.2 Hz, ArH), 7.31 (dd, 1H, J
8.8 Hz, 2.4 Hz, ArH), 7.36–7.60 (m, 8H, ArH and NH), 9.52 (br s, 1H, OH), 11.33 (s, 1H, NHCO). 13C
NMR (100 MHz: DMSO-d6): δ 45.58, 55.98, 72.10, 110.09, 115.82, 116.02, 116.78, 121.26, 122.41, 125.77,
127.10, 127.54, 129.24, 129.60, 133.73, 139.92, 144.50, 146.47, 147.68, 148.33, 149.17, 162.40, 164.19,
168.95. Isomer Z (23%): 1H NMR (400 MHz: DMSO-d6): δ 3.35 (d, 1H, J 16.4 Hz, α-CH), 3.81 (s, 3H,
CH3O), 4.50 (d, 1H, J 16.4 Hz, α-CH), 6.01 (s, 1H, sp
3 C-H), 6.74 (d, 1H, J 8.8 Hz, ArH), 6.82 (d, 1H, J
8.0 Hz, ArH), 6.99 (dd, 1H, J 8.4 Hz, 1.2 Hz, ArH), 7.26 (d, 1H, J 1.2 Hz, ArH), 7.31 (dd, 1H, J 8.8 Hz,
2.4 Hz, ArH), 7.36–7.60 (m, 8H, ArH and NH), 9.52 (br s, 1H, OH), 11.25 (s, 1H, NHCO). 13C NMR
(100 MHz: DMSO-d6): δ 46.37, 55.96, 72.20, 109.55, 115.62, 115.87, 116.81, 121.42, 122.41, 125.97, 127.10,
127.40, 129.29, 129.60, 133.84, 139.92, 144.50, 146.32, 147.68, 148.44, 149.40, 162.44, 164.19, 168.95.
Anal. Calcd for C24H21ClN4O4: C, 62.00; H, 4.55; N, 12.05. Found: C, 61.81; H, 4.65; N, 12.13.
royalsocietypublishing.org/jou
154.1.5. 2-(((E)-benzylidene)amino)-5-chloro-N-(2-(2-((E)-4-hydroxy-3-methoxybenzylidene)hydrazinyl)-2-
oxoethyl)benzamide (6)
Yield: 36%; mp 257–259°C. 1H NMR (400 MHz: DMSO-d6): δ 3.64 (s, 2H, CH2), 3.86 (s, 3H, CH3O), 6.99
(d, 1H, J 7.2 Hz, ArH), 7.18 (d, 1H, J 8.8 Hz, ArH), 7.30 (s, 1H, ArH), 7.36 (d, 1H, J 7.2 Hz, ArH), 7.42 (s,
1H, ArH), 7.55–7.60 (m, 6H, ArH), 7.63 (s, 1H, ArH), 7.71 (s, 1H, ArH), 8.74 (s, 1H, NHCH2), 8.80 (s, 1H,
NHCO), 10.53 (s, 1H, OH). 13C NMR (100 MHz: DMSO-d6): δ 44.75, 56.05, 110.85, 116.05, 116.08, 123.10,
123.52, 124.63, 124.90, 127.53, 128.34, 130.40, 132.52, 136.62, 148.53, 148.58, 151.23, 151.83, 161.26, 166.88,
167.29, 171.30. Anal. Calcd for C24H21ClN4O4: C, 62.00; H, 4.55; N, 12.05. Found: C, 62.21; H, 4.71; N,
12.30.rnal/rsos
R.Soc.Open
Sci.7:2000504.1.6. Methyl 2-(4-oxo-2-phenylquinazolin-3(4H)-yl)acetate (8)
To a solution of compound 3a (0.75 g, 2.54 mmol) in ethyl acetate (50 ml), 2,3-dichloro-5,6-dicyano-p-
benzoquinone DDQ (0.691 g, 3.048 mmol) was added. The reaction mixture was stirred for 3 h,
concentrated, and left to cool to room temperature. The product was purified by column
chromatography using silica gel as stationary phase and ethyl acetate–methanol (8 : 2) as mobile
phase. Yield: 89%; mp 115–116°C [Lit. [29] 150°C]. IR (KBr): 1750 (C=O, ester), 1688 (C=O, amide)
cm−1. 1H NMR (400 MHz: DMSO-d6): δ 3.64 (s, 3H, OCH3), 4.66 (s, 2H,CH2), 7.57 (bs, 5H, Ar-H), 7.62
(t, 1H, J 8 Hz, Ar-H), 7.74 (d, 1H, J 8 Hz, Ar-H), 7.91 (t, 1H, J 8 Hz, Ar-H), 8.2 (d, 1H, J 8 Hz, Ar-H).
13C NMR (100 MHz: DMSO-d6): δ 47.86, 61.82, 120.32, 126.72, 127.90, 128.40, 129.17, 130.62, 134.95,
135.54, 147.35, 155.94, 161.62, 168.36, 168.87.4.1.7. 2-(4-oxo-2-phenylquinazolin-3(4H)-yl)acetohydrazide (7)
To a solution of compound 8 (0.294 g, 1 mmol) in methanol (10 ml), hydrazine hydrate (80%) (0.4 ml)
was added. The reaction mixture was heated under reflux for 3 h and monitored by TLC (EtOAc :
MeOH 7 : 3). The solution was concentrated and the product that precipitated out was filtrated off,
recrystallized from ethanol and dried. Yield: 87%; mp 215–218°C. IR (KBr): 3350, 3300 (NH2 and NH),
1690 (C=O, amide) cm−1.4.1.8. Methyl 2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetate (10)
A mixture of compound 9 (1.03 g, 3 mmol), and triethylamine (0.636 g, 3 mmol), glycine methyl ester
hydrochloride (0.803 g, 3 mmol). The reaction mixture was heated in an oil-bath at temperature of
120°C for 1 h, and the reaction was followed by TLC (EtOAc :MeOH 7 : 3). The crude residue was
recrystallized from methanol and dried. Yield: 46%; mp 115–117°C [lit. 115°C [35]].4.1.9. 2-(2-Methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide (11)
To a solution of compound 10 (0.5 g, 2.15 mmol) in dimethylformamide (10 ml), hydrazine hydrate (80%,
0.25 ml) and two drops of anhydrous acetic acid were added. The reaction mixture was heated under
reflux for 5 h and followed by TLC (EtOAc :MeOH 7 : 3). The reaction mixture was left to cool to
room temperature and the product that separated out was filtered off and recrystallized from ethanol,
yield= (79%), mp 256°C decomp. [lit. [35] 260°C]. IR (KBr): 3267, 3142 (NH2 and NH), 1670 (C=O,
amide) cm-1. 1H NMR (400 MHz: DMSO-d6): δ 2.50 (s,3H,CH3), 3.41 (bs, 2H, NH2), 4.38 (s, 2H, CH2),
7.49 (t, 1H, J 7.6 Hz, Ar-H), 7.61 (d, J 7.6 Hz, 1H, Ar-H), 7.81 (t, J 7.6 Hz, 1H, Ar-H), 8.08 (d, J 7.6 Hz,
1H, Ar-H), 8.83, 9.44 (s, bs, 1H, NH). 13C NMR (100 MHz: DMSO-d6): δ 22.26, 44.20, 119.13, 125.56,
125.65, 125.82, 133.83, 146.51, 154.77, 160.50, 165.70.4.1.10. General procedures for the preparation of N’-substituted benzylidene-2-(2-methyl-4-oxoquinazolin-
3(4H)-yl)acetohydrazide (12a–12d)
To a solution of compound 11 (1.624 g, 7.00 mmol) in dimethylformamide (10 ml), the appropriate
aldehyde (7.00 mmol) and two drops of anhydrous acetic acid were added. The reaction mixture was
heated under reflux for 5 h and the mixture was left to cool to room temperature. The product that
precipitated out was filtrated off, recrystallized from ethanol and dried.
royalsocietypublishing.
164.1.10.1. N’-Benzylidene-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide (12a)
Yield: 64%; mp 242–245°C [lit. [32] 245°C]. IR (KBr): 3223 (NH), 1680 (C=O, amide) cm−1. Isomer E (80%):
1H NMR (400 MHz: DMSO-d6): δ 2.56 (s, 3H, CH3), 5.33 (s, 2H, CH2), 7.46–8.12 (m, 10H, Ar-H), 11.85 (s,
1H, NH). 13C NMR (100 MHz: DMSOd6): δ 23.31, 45.70, 120.08, 126.67, 126.84, 127.06, 127.45, 129.31,
130.59, 134.35, 135.01, 144.93, 147.66, 155.91, 161.69, 169.73. Isomer Z (20%): 1H NMR (400 MHz:
DMSO-d6): δ 2.51 (s, 3H, CH3), 4.90 (s, 2H, CH2), 7.46–8.25 (m, 10H, Ar-H), 11.90 (s, 1H, NH).
13C
NMR (100 MHz: DMSOd6): δ 23.46, 46.10, 120.10, 126.63, 126.87, 127.06, 127.62, 129.31, 130.66, 134.49,
135.04, 147.61, 147.75, 155.86, 164.00. MS-ESI: m/e 321.1 [M+1] (calcd for C18 H16N4O2). org/journal/rsos
R.Soc.Open
Sci.7:200054.1.10.2. N’-(4-Hydroxybenzylidene)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide (12b)
Yield: 86%; mp 192–195°C. IR (KBr): 3210, 3100 (br.) (OH and NH), 1680 (C=O, amide) cm-1. Isomer E
(77%): 1H NMR (400 MHz: DMSO-d6): δ 2.56 (s, 3H, CH3), 5.30 (s, 2H, CH2), 6.83–6.87, 7.49–7.65,
7.80–7.84, 7.99–8.10–8.14 (m, m, t, s, m, 9H, Ar-H), 9.97 (s, 1H, OH), 11.65 (s, 1H, NH). 13C NMR
(100 MHz: DMSO-d6): δ 23.30, 45.66, 116.18, 120.09, 125.38, 126.67, 126.80, 127.04, 129.20, 134.97,
145.21, 147.66, 155.93, 159.89, 161.69, 168.32. Isomer Z (23%): 1H NMR (400 MHz: DMSO-d6): δ 2.51
(s, 3H, CH3), 4.88 (s, 2H, CH2), 6.83–6.87, 7.49–7.65, 7.80–7.84, 7.99–8.10–8.14 (m, m, t, s, m, 9H, Ar-
H), 9.97 (s, 1H, OH), 11.70 (s, 1H, NH). 13C NMR (100 MHz: DMSO-d6): δ 23.45, 46.08, 116.18, 120.12,
125.45, 126.64, 126.84, 129.40, 135.00, 147.61, 148.04, 155.87, 159.99, 163.57. MS-ESI: m/e 337.0 [M+1]
(calcd for C18H16 N4O3.). Anal. Calcd for C18H16N4O3: C, 64.28; H, 4.79; N, 16.66. Found: C, 64.50; H,
5.02; N, 16.84. 04.1.10.3. N’-(4-Methoxybenzylidene)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide (12c)
Yield: 77%; M.P.: >229°C decomp. [lit. [32] 230°C] IR (KBr): 3400 (NH), 1690 (C=O, amide) cm−1. Isomer
E (78%): 1H NMR (400 MHz: DMSO-d6): δ 2.52 (s, 3H, CH3), 3.81 (s, 3H, OCH3), 5.31 (s, 2H, CH2), 7.02–
7.07, 7.49–7.53, 7.62–7.71, 7.81–7.83, 8.03–8.19 (t, t, d, d, d, s, d, s, 9H, Ar-H), 11.72 (s, 1H, NH). 13C NMR
(100 MHz: DMSOd6): δ 23.30, 45.67, 55.77, 114.80, 120.09, 126.66, 126.82, 127.04, 129.06, 130.40, 134.99,
144.80, 147.66, 155.93, 161.06, 161.31, 161.69, 163.63. Isomer Z (22%): 1H NMR (400 MHz: DMSO-d6): δ
2.56 (s, 3H, CH3), 3.83 (s, 3H, OCH3), 4.88 (s, 2H, CH2), 7.02–7.07, 7.49–7.53, 7.62–7.71, 7.81–7.83,
8.03–8.19 (t, t, d, d, d, s, d, s, 9H, Ar-H), 11.77 (s, 1H, NH). 13C NMR (100 MHz: DMSOd6): δ 23.40,
46.03, 55.84, 114.86, 120.12, 126.63, 126.85, 126.94, 129.23, 130.40, 135.02, 144.80, 147.61, 155.88, 161.06,
161.39, 162.14, 168.44. MS-ESI: m/e 350.7 [M+1].4.1.10.4. N’-(4-Hydroxy-3-methoxybenzylidene)-2-(2-methyl-4-oxoquinazolin-3(4H)-yl)acetohydrazide (12d)
Yield: 72%; mp 258–260°C. IR (KBr): 3294 (br), 3180 (br) (OH and NH), 1699, 1686 (C=O, amide) cm-1.
Isomer E (81%): 1H NMR (400 MHz: DMSO-d6): δ 2.61 (s, 3H, CH3), 3.84 (s, 3H, OCH3), 5.31 (s, 2H,
CH2), 6.85–8.23 (m, 8H, Ar-H), 9.47 (s, 1H, OH), 11.68 (s, 1H, NH).
13C NMR (100 MHz: DMSOd6): δ
23.32, 45.29, 110.0 7, 116.01, 120.08, 120.21, 121.98, 125.78, 126.63, 126.75, 126.86, 127.06, 134.89, 145.36,
147.58, 148.45, 149.42, 155.91, 166.79, 168.23. Isomer Z (19%): 1H NMR (400 MHz: DMSO-d6): δ 2.59
(s, 3H, CH3), 3.81(s, 3H, OCH3), 4.88 (s, 2H, CH2), 6.85–8.23 (m, 8H, Ar-H), 9.58 (s, 1H, OH), 11.76 (s,
1H, NH). 13C NMR (100 MHz: DMSOd6): δ 23.18, 45.73, 109.65, 115.91, 120.17, 122.49, 125.86, 126.65,
126.70, 126.83, 126.99, 135.00, 147.55, 148.45, 149.54, 166.15, 167.79. MS-ESI: m/e 336.4 [M+1]. Anal.
Calcd for C19 H18 N4O4: C, 62.29; H, 4.95; N, 15.29. Found: C, 62.17; H, 5.01; N, 15.43.4.2. MAO activity screening
The activity of MAO was determined using the coupled assay method of [41,42] in which the product,
H2O2, acts with horseradish peroxidase to convert 10-acetyl-3,7-dihydroxyphenoxazine to the fluorescent
resorufin. All compounds were screened for inhibition of the activity of membrane-bound human MAO-
A and B at 10 μM in the presence of 2 ×Km tyramine (an assay concentration of 0.8 mMwith MAO-A and
0.32 mM with MAO-B). For compounds that gave more than 30% inhibition, the IC50 was determined
using seven concentrations of each compound (0.01–300 μM) with substrate at 2 ×KM. The IC50 values
are the mean and standard deviation for two separate experiments (16 and 22 points, respectively).
The data were analysed using the equation for a three-parameter curve in Graphpad PRISM v. 4, and
the % inhibition calculated from the top and bottom of the resulting curve.
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174.3. Docking studies
Molecular docking studies were carried out to understand the molecular binding modes of the active
synthesized compounds towards two different biological targets the human MAO enzymes. The
Protein Data Bank (PDB) crystallographic structures of human MAO-A (PDB ID: 2BXR) and human
MAO-B (PDB ID: 2BYB) were prepared by the removal of the co-crystallized ligands [42]. Before
screening the new compounds, the docking protocol was validated by running the simulation using
these ligands, and low RMSD between docked and crystal conformations was obtained. AutoDock 3.0
[43] and MOE [44] softwares were used for all docking calculations. The AutoDockTools package was
employed to generate the docking input files and to analyse the docking results. A grid box size of
90 × 90 × 90 points with a spacing of 0.375 Å between the grid points was generated that covered
almost the entire protein surface. All non-polar hydrogens and crystallographic water molecules were
removed prior to the calculations. The docking grid was centred on the mass centre of the bound
drugs. Ligands were fully flexibly docked. In each case, 100 docked structures were generated using
genetic algorithm searches. A default protocol was applied with an initial population of 50 randomly
placed conformations, a maximum number of 2.5 × 105 energy evaluations and a maximum number of
2.7 × 104 generations. Heavy atom comparison root mean square deviations (RMSD values) were
calculated and initial ligand binding modes were plotted. Protein–ligand interaction plots were
generated using MOE 2012 [45].
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